Prostate Cancer: Best Practices for Combining Targeted Therapies in mPC

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Therapeutic Area

Region

Submission Countdown

Days
Hours

Date RFP Issued: Mar 12, 2026

Geographic Scope: United States

Clinical Area: Oncology – Genitourinary

Application Due Date: Apr 28, 2026

Specific Area of Interest: Potential applicants are encouraged to identify and address educational gaps relating to optimal application and management of targeted therapies for patients with mPC in diverse clinical practice settings. This may include education related to:

· Guideline concordance and best practices for integration of testing into clinical practice

· Existing and emerging data on the efficacy and safety regarding PARPi’s

· Clinical data regarding PARPi combinations and how to mitigate associated side effects

PIRA™ suggested Proposal

PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.